A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
기사 요약
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
신뢰할 수 있는 매체의 최신 소식을 간단한 요약과 함께 확인하세요. 자세한 내용은 원문 링크를 여세요.